Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495459 | 0.93 | SMN1; SMN2 (0.42) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4815638 | 0.86 | SMN1; SMN2 (0.46) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4815629 | 0.86 | SMN1; SMN2 (0.46) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL23817652 | 0.84 | EPHX2 (0.47) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL27914158 | 0.84 | ALDH1A1 (0.53) | HIF1ACYP2D6ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL18559671 | 0.83 | EPHX2 (0.46) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL16518667 | 0.83 | EPHX2 (0.46) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL15506158 | 0.83 | EPHX2 (0.46) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL15577026 | 0.83 | EPHX2 (0.46) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4550437 | 0.83 | CYP3A4 (0.43) | CYP3A4HIF1ACYP2D6ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-25 | — | — | US | claimed |
| EP-1981854-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-01 | — | — | EP | claimed |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-03 | — | — | US | claimed |
| US-7842708-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | claimed |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | claimed |
| EP-1981854-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-10-22 | — | — | EP | claimed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | claimed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2021119249-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-9598418-B2 | Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 | CADILA HEALTHCARE LIMITED (IN) | 2017-03-21 | — | — | US | disclosed |
| US-9580409-B2 | Modulators of opioid receptors and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580409-B2 | Modulators of opioid receptors and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | CADILA HEALTHCARE LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | PHENEX PHARMACEUTICALS AG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | CYP3A4 670/4885HIF1A 1409/4885CYP2D6 1381/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | CYP3A4 670/4885HIF1A 1409/4885CYP2D6 1381/4885 |
| US-20150291603-A1 | SUBSTITUTED PHTHALAZIN-1 (2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1 | PARP1, PARP11, PARP2 | CYP3A4 1493/4885HIF1A 3315/4885CYP2D6 1032/4885 |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | RORA, RORB, RORC | CYP3A4 879/4885HIF1A 740/4885CYP2D6 1162/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | CYP3A4 932/4885HIF1A 4088/4885CYP2D6 865/4885 |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | CYP3A4 670/4885HIF1A 1409/4885CYP2D6 1381/4885 |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | CYP3A4 670/4885HIF1A 1409/4885CYP2D6 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.